摘要 |
Disclosed are: an HLA-A*-1101-restricted WT1 peptide, specifically a peptide which comprises an amino acid sequence composed of nine contiguous amino acid residues derived from WT1 protein, is capable of binding to an HLA-A* 1101 molecule and has a CTL-inducing ability; a peptide dimer which comprises two peptide monomers each comprising an amino acid sequence composed of nine contiguous amino acid residues containing at least one cysteine residue and derived from WT1 protein, wherein the two peptide monomers are linked to each other via a disulfide bond and the peptide dimer is capable of binding to an HLA-A* 1101 molecule and has a CTL-inducing ability; a polynucleotide encoding the peptide; a pharmaceutical composition for the treatment and/or prevention of cancer, which comprises the peptide or the peptide dimer; and others. |